Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 11/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937612 | 0.79 | TYMS (0.62) | TYMSCES1ALOX15TDP1DHFR | |
| SCHEMBL322393 | 0.79 | TYMS (0.62) | TYMSCES1ALOX15TDP1DHFR | |
| SCHEMBL9995282 | 0.79 | CES1 (0.57) | TYMSCES1NPSR1DHFRCYP1B1 | |
| SCHEMBL2594282 | 0.79 | TYMS (0.61) | TYMSCES1ALOX15TDP1TSHR | |
| SCHEMBL30694295 | 0.75 | CES1 (0.41) | TYMSCES1NPSR1DHFRCYP1B1 | |
| SCHEMBL3850862 | 0.75 | NPSR1 (0.59) | CES1NPSR1TDP1CYP1B1 | |
| SCHEMBL3682903 | 0.75 | MAPK1 (0.46) | CES1NPSR1TSHRCYP1B1 | |
| SCHEMBL580216 | 0.75 | CES1 (0.65) | TYMSCES1ALOX15TDP1TSHR | |
| SCHEMBL127867 | 0.74 | TSHR (0.54) | TYMSALOX15TDP1TSHR | |
| SCHEMBL29713398 | 0.74 | TYMS (0.64) | TYMSNPSR1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438106-B1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | BOEING CO (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2438106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | The Boeing Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8106142-B2 | Polyacetylinic oligomers | THE BOEING COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8063168-B2 | Oligomers with di-phenylethynyl endcaps | THE BOEING COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010141106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204412-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
| EP-0939754-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998019648-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | AADAC, ACMSD, ECPAS | TYMS 3057/4885CES1 4127/4885NPSR1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.